Bicycle Therapeutics (Nasdaq: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, is today hosting a Research & Development (R&D) Day for investors and analysts in New York to provide clinical updates for BT8009, BT748
Nectin-4 portfolio comprised of BT8009 and BT7480 represents potential opportunity to become leader in treating Nectin-4-driven cancers, starting with metastatic urothelial cancer
Updated BT8009.
Bicycle Therapeutics Plc (BCYC) Provides Data Updates for Three Clinical Programs and Strategy Overview streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Alignment with U.S. FDA on design of Phase 2/3 registrational trial, to be initiated in 1Q 2024
Innovative study design allows for potential accelerated approval in untreated and previously.